Acute Ischemic Heart DiseaseThe use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2☆,☆☆,★
Section snippets
Data sources
NRMI 2 is a prospective, observational study sponsored by Genentech, Inc (South San Francisco, Calf). NRMI 2, which was initiated in June 1994, contains data abstracted from the charts of patients with AMI admitted to registry hospitals. The completed case report form is forwarded from the registry hospital to an independent central data collection center (ClinTrials Research, Inc, Lexington, Ky) for processing and analysis. The data collection center used double-key entry to add data from each
Results
By using data from NRMI 2, we identified 23,180 patients with AMI complicated by cardiogenic shock. The baseline demographic and clinical characteristics of this population are shown in Table I.Patient characteristics (n = 23,180) Empty Cell Age (y) 71.9 Male sex 53.7% White race 87.1% History of Diabetes 31% Hypertension 48% Angina 20% CHF 20% MI 28% Stroke 11% PTCA 6% CABG 12% Chest pain on arrival 62% Killip class IV on arrival 25% ST
Discussion
In this study, we made several important observations regarding the treatment and outcome of patients with AMI complicated by cardiogenic shock. First, the mortality rate in patients with cardiogenic shock remains exceedingly high (70%) and does not appear to have significantly changed over time. In a community-based study in Worcester, Massachusetts, Goldberg et al3 found that the overall in-hospital mortality rate of patients with AMI complicated by cardiogenic shock was 78% and was constant
References (21)
- et al.
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience: the GUSTO-I Investigators: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
J Am Coll Cardiol
(1995) - et al.
Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era
J Am Coll Cardiol
(1992) - et al.
Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography
Am J Cardiol
(1985) Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock
Am Heart J
(1993)- et al.
Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator
J Am Coll Cardiol
(1992) - et al.
Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent
J Am Coll Cardiol
(1994) - et al.
The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction: the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group
Am Heart J
(1991) - et al.
Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy
J Am Coll Cardiol
(1996) - et al.
Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital
Chest
(1994) - et al.
Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock
J Am Coll Cardiol
(1991)
Cited by (282)
Percutaneous Mechanical Circulatory Support in Post–Myocardial Infarction Cardiogenic Shock: A Systematic Review and Meta-analysis
2022, Canadian Journal of CardiologyMechanical Circulatory Support in Acute Myocardial Infarction and Cardiogenic Shock
2021, Interventional Cardiology ClinicsHow to Bail Out Patients with Severe Acute Myocardial Infarction
2020, Heart Failure ClinicsIs there still a role for the intra-aortic balloon pump in the management of cardiogenic shock following acute coronary syndrome?
2019, Archives of Cardiovascular Diseases
- ☆
Supported in part by a grant from Datascope Corp, Montiale, NJ, and Genentech Inc, South San Francisco, Calif.
- ☆☆
Reprint requests: Hal V. Barron, MD, 1 DNA Way, South San Francisco, CA 94080. E-mail: [email protected]
- ★
The first author, Hal V. Barron, is an employee of Genentech Inc, South San Francisco, Calif.